BACKGROUND: CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and gene expression in Chinese patients. METHODS: A total of 665 patients diagnosed with PCa and 703 cancer-free controls were genotyped in this hospital-based case-control study, and 26 PCa tissue samples were evaluated for mRNA expression of CYR61 by real-time quantitative reverse-transcription PCR. RESULTS: Men carrying the G allele of rs3753793 (TG þ GG) had significantly lower risk of PCa when compared with the TT genotype (odds ratio (OR) ¼ 0.76, 95% confidence interval (CI) ¼ 0.61-0.95). The association was generally more pronounced among subgroups of PCa patients with advanced stage (OR ¼ 0.70, 95% CI ¼ 0.53-0.94), Gleason score 47 (OR ¼ 0.63, 95% CI ¼ 0.46-0.86) and PSA420 ng ml À 1 (OR ¼ 0.68, 95% CI ¼ 0.53-0.88). Prostate tumors derived from cases with the GT/GG genotypes had significantly lower levels of CYR61 mRNA when compared with cases with the TT genotypes (P ¼ 0.02). CONCLUSIONS: Our results indicate that the genetic variation of rs3753793 in the CYR61 promoter may contribute to genetic predisposition to PCa and intra-tumor expression gene expression.
INTRODUCTION
Prostate cancer (PCa) is widely regarded as the most common malignant tumor in men and the second leading cause of cancer mortality in developed countries. In 2010, an estimated 217 730 new cases are expected to be diagnosed, and 32 050 deaths will occur in the United States alone. 1 Known risk factors for PCa include age, race/ethnicity, genetic background, environmental factors and sex steroid hormone levels. 2 Although epidemiological studies have established that Asian men have lower risk of PCa, 3 the underlying etiological factors accounting for racial differences in PCa risk remain poorly understood. In China, as lifestyle becomes more westernized, there has been an appreciable increase of PCa mortality rate (from 1.5/100 000 in 2000 to 1.7/ 100 000 in 2005). 4 Investigation of genetic risk factors for PCa in this population may be facilitated by a candidate gene approach.
The CCN (CTGF, Cyr61 and Nov) family is named after three members of a set of immediate-early genes, CYR61 (CCN1), CTGF (CCN2) and NOV (CCN3), which are rapidly expressed after exposure to polypeptide growth factors.
5 CYR61 (cysteine-rich protein 61), located on 1p22, was the first cloned member of the CCN family. The CYR61 protein has been shown to participate in a number of key cellular processes, including cell adhesion, migration, proliferation, differentiation, wound healing and angiogenesis. 6, 7 An increasing body of evidence suggests that CYR61 participates in the development and progression of various cancers. 8 Elevated expression of CYR61 has been detected in the invasive breast cancer cell lines, pancreatic cancers and pediatric tumors. 7, 9, 10 CYR61 was recently shown to promote growth and metastasis of prostate tumors. 11 One polymorphic variant in the promoter region of the CYR61 gene, rs3753793 (G4T), was shown to be associated with plasma high-density lipoprotein-cholesterol levels in obese individuals. 12 To date, there is no report investigating the role of CYR61 polymorphism in PCa. The objective of this study is to evaluate the association between rs3753793 (G4T) polymorphism and PCa in the Chinese population.
MATERIALS AND METHODS

Study subjects
A total of 665 PCa patients diagnosed through needle biopsy were recruited from the First Affiliated Hospital of Nanjing Medical University, starting from December 2003. The controls were recruited from those seeking routine outpatient care at the same hospital. All the controls were screened with directeral rectun examination before the recruitment to be presumed to be cancer-free. All subjects were unrelated ethnic southern Han Chinese. At recruitment, informed consent was obtained from each participant. Interviews were conducted to collect detailed information, including age, tobacco use, alcohol use and family history of cancer. In this study, individuals that smoked daily for more than 1 year were defined as smokers and the other as nonsmokers. Pack-years of smoking (cigarettes per day/20) Â years smoked were calculated to indicate the cumulative smoking dose. Drinking habit was defined as drinking at least three times per week and lasting more than 6 months, and the rest were defined as never drinkers. Family history of cancer was defined as any cancer in first-1 degree relatives (parents, siblings or children). Disease stage was determined by pathological findings, pelvic computed tomography, magnetic resonance imaging and radio-nucleotide bone scans. The tumor stage was determined using the international tumor node metastasis classification and graded according to the WHO guidelines. On the basis of the tumor node metastasis classification system promulgated by the American Joint Committee on Cancer, the disease stage was divided into localized and advanced cancer. Localized PCa was defined as detectable clinically or felt (palpated) on examination, but had not spread outside the prostate (T 1-2 N 0 M 0 ). Advanced PCa was defined as those that had spread outside the prostate (T 3-4 N x M x , or T x N 1 M x or T x N x M 1 ). Pathologic grade was evaluated by the Gleason score. Each subject donated 5 ml of blood for genomic DNA extraction. The research protocol was approved by the institutional review board of Nanjing Medical University.
Genotyping
Genomic DNA was isolated and purified from leukocytes in anti-coagulated blood, using the traditional phenol/chloroform extraction and ethanol precipitation, dissolved in TE buffer (pH 7.4) and stored at À 20 1C for genotyping. The CYR61 rs3753793 (G4T) polymorphism was determined by the PCR-restriction fragment length polymorphism method. The PCR primers for the CYR61 rs3753793 (G 4T) were 5 0 -CTTGCCTCTCACCTTCGCT GTTAA-3 0 (forward) and 5 0 -GTCGTTTTGTTTGGTGATGCGA-3 0 (reverse). The PCR reactions were carried out in a total volume of 20 ml containing 50 ng genomic DNA, 10 Â Taq buffer, 0.02 mmol l À 1 of MgCl 2 , 0.05 mmol l À 1 of dNTP mix, 10 pmol ml À 1 of each primer and 1 U Taq DNA polymerase. After initial denaturation at 95 1C for 5 min, the reaction was carried out at 95 1C denaturation for 30 s, 57 1C annealing for 40 s and 72 1C extension for 45 s for a total of 34 cycles, and a final elongation at 72 1C for 10 min. The 104-bp amplified products were incubated with 5 U of KspAI (MBI Fermentas, Burlington, Ontario, Canada) restriction enzyme at 37 1C overnight. The restriction fragments were then analyzed by electrophoresis in 3% agarose gel stained with 0.5% ethidium bromide and photographed under ultraviolet illumination. Digestion with KspAI yielded 80 bp, and it yielded 24 bp fragments only when G allele was present (Figure1). To ensure quality control, genotyping was performed by two persons independently in a blinded fashion. A 10% random sample of cases and controls was genotyped twice by different persons, and the results were 100% concordant.
RNA extraction and real-time quantitative reverse-transcription PCR
To further detect the correlation between the CYR61 mRNA levels and rs3753793 polymorphism in vivo, radical prostatectomy specimens was obtained from 26 cases with different genotypes. Tumor tissues were prepared by laser-capture microdissection. Total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. All RNA samples were quantified spectrophotometrically. An aliquot of the total RNA (1 mg) from each tumor tissue was reverse transcribed into single-strand cDNA using an oligo (dT) 15 primer and Superscript II (Invitrogen), and the gene expression was measured by real-time quantitative reverse-transcription PCR. The primers used for PCR amplification were 5 0 -CCTGTCCGCTGCACACCAGC-3 0 (forward) and 5 0 -GGAGAGCGCCAGCCTGGTCA-3 0 (reverse) for CYR61; and 5 0 -GAAATCCC ATCACCATCTTCCAGG-3 0 (forward) and 5 0 -GAGCCCCAGCCTTCTCCATG-3 0 (reverse) for glyceraldehydes-3-phosphate dehydrogenase (GAPDH). The expression of CYR61 relative to GAPDH RNA was determined using the 2 À dCT method as described. 13 
Statistical analysis
Pearson's w 2 -test was used to examine differences in demographic variables, pack-years of smoking, smoking status, alcohol use, family history of cancer and genotype frequencies of rs3753793 between the cases and controls. The association between the polymorphisms and risk of PCa was estimated by odds ratios (ORs) and their 95% confidence intervals (CIs), which were calculated by unconditional logistic regression. All ORs were adjusted for age, cigarette smoking and drinking status. All tests to determine statistical significance were two-sided, and Po0.05 was considered statistically significant. All statistical analyses were performed with Statistics Analysis System software (Version 9.1.3; SAS Institute, Cary, NC, USA).
RESULTS
Characteristics of the study population
The frequency distributions of selected characteristics of the cases and controls are shown in Table 1 . There were no differences between the cases and controls on age (P40.05). However, the frequency of smokers and drinkers from the case group was higher when compared with the control group (57.3 versus 50.5%, P ¼ 0.007; 29.6 versus 24.6%, P ¼ 0.037, respectively). Moreover, a significantly higher proportion of cases were positive for family tumor history compared with controls. The number of subjects Stratification analysis between CYR61 polymorphism and risk of PCa We further evaluated the effect of rs3753793 polymorphism on PCa risk stratified by age, smoking status, pack-years of smoking, drinking status and family history of cancer. As shown in Table 3 , although the decreased risk of PCa associated with the combined variant genotypes (TG/GG) tend to be more evidenced in subjects who were older (471 years), nonsmokers, nondrinkers and negative for family history, these discrepancy may be attributed to chance (all P40.05, test for heterogeneity; Table 3 ). We further evaluated the association between rs3753793 and clinicopathological characteristics of PCa. As shown in Association of the CYR61 polymorphism with intra-tumor expression of CYR61 mRNA We collected 26 fresh-frozen tumor samples obtained from patients treated with radical prostatectomy and with matched genotyping data. The distribution of the GG, TG and TT genotypes was 1 (3.85%), 13 (50.00%) and 12 (46.15%), respectively. The effect of these three genotypes on CYR61 mRNA expression was evaluated by real-time quantitative reverse-transcription PCR.
CYR61 quantification showed that homozygous carriers of the T allele had significantly increased mRNA levels when compared with carriers of the TG/GG genotype (P ¼ 0.02; Figure 2 ).
DISCUSSION
In the present study, we investigated whether a single-nucleotide polymorphism (rs3753793) in the promoter region of the CYR61 gene is associated with PCa risk in a Chinese population. We found that the GG and TG genotypes were associated with significantly decreased risk for PCa when compared with the TT genotype, and the decreased risk was more pronounced among subgroups of PCa patients with advanced stage, Gleason score 47, or PSA420 ng ml
. In addition, we found that prostate tumors derived from carriers of the TT genotype had significantly increased mRNA levels compared with carriers of the GG and TG genotypes.
A number of previous studies established the importance of CYR61 in tumor biology and thus corroborate our findings. First, CYR61 is a secreted, integrin-binding protein involved in cell proliferation, survival, apoptosis, adhesion and migration. Increased expression of CYR61 is associated with pathological conditions in which angiogenesis has an important role, [14] [15] [16] [17] and may mediate signaling through interacting with integrin a v b 3 . 15, 18, 19 In addition, many previous studies have demonstrated that overexpression of CYR61 is associated with tumor growth and progression. 20, 21 Second, enhancement of cell survival has been proposed as an alternative pro-tumorigenic mechanism of CYR61, as forced expression of CYR61 in breast carcinoma cells promotes resistance to apoptosis by upregulating the expression of XIAP, an anti-apoptotic protein. 22 Similarly, Menendez et al. 23 reported that elevated expression of CYR61 confers resistance to the proapoptotic anti-cancer drug Taxol. Third, Sakamoto et al. 24 demonstrated that CYR61 had functional roles in prostatic cell morphology, adhesion and proliferation, supporting its involvement in benign prostatic enlargement. Moreover, many cell line models have been used to support the pro-tumorigenic role of CYR61 in PCa.
11,14 Marra et al. 25, 26 have demonstrated the role of CYR61 in the desensitization of PCa cells to the anti-tumor effects of zoledronic acid and suggested CYR61 as a potential molecular target for the potentiation of anti-cancer effects of zoledronic acid in PCa. In our study, we found that the association between rs3753793 polymorphism and the risk of PCa appeared stronger in the subgroups of nonsmokers (OR ¼ 0. Adjusted for age, smoking status, drinking status and family history of cancer in logistic regression model. The bold entries mean the data is significant or mentioned in the article.
CYR61 polymorphism and prostate cancer L Tao et al that genetic variants of CYR61 may contribute to the susceptibility of PCa by modulating its expression levels. A previous study analyzed a 936-bp functional promoter fragment of the human CYR61 gene. 27 To our knowledge, our study is the first to report the effect of a functional polymorphism in the CYR61 gene on CYR61 mRNA in PCa tissues. However, Bouchard et al. 12 did not find any association between rs3753793 polymorphism and omental adipose tissue CYR61 mRNA levels in obese individuals. The possible explanation is that this polymorphism may affect CYR61 transcriptional activity differently in different tissues or diseases. Further investigations are needed to dissect the regulatory mechanisms regarding how genetic variants affect mRNA expression in different tissue context.
PCa remains multifactorial in etiology and heterogeneous in its development and disease progression. However, no significant Adjusted for age, pack-years of smoking, drinking status and family history of cancer in logistic regression model. The bold entries mean the data is significant or mentioned in the article.
CYR61 polymorphism and prostate cancer L Tao et al association were observed in the stratified analysis by the securable risk factors, indicating that the CYR61 polymorphism was an independent risk factor of PCa and the latent confounding factors had no significant modification effect on it. In addition, we observed a statistically significant protective effect of the G allele of rs3753793 for developing advanced PCa, suggesting that the polymorphism may be associated with progression of established tumors. As the G allele is associated with decreased mRNA level of CYR61, reduced CYR61 production in patients with the rs3753793 G allele may have protective effect on PCa progression. This notion is supported by study findings establishing CYR61 as an important paracrine growth factor to promote the metastasis of malignant PCa cells.
11
However, D'Antonio et al. 28 found that high CYR61-staining intensity in adenocarcinoma was associated with a lower risk of recurrence after surgical treatment of PCa. More studies are needed to address the role of CYR61 in PCa progression and to explain the discrepancies.
The allele and genotype frequencies of rs3753793 vary with race/ethnicity. In our study with 703 healthy control subjects, the frequencies of the TT, GT and GG genotypes of the rs3753793 were 42.0, 48.0 and 10.0%, respectively, compared with 58.6, 36.1 and 5.3%, respectively, of 697 cancer-free Caucasian in the study by Bouchard et al. 12 Curiously, the incidence of PCa in Chinese populations is much lower than what is observed in Caucasians. Racial/ethnic variation in the rs3753793 genotype distribution warrants additional comparative studies with more participants to confirm our results.
Some limitations of this study should be addressed. First, our sample size was small and lack detailed information on environmental factors, such as diet, physical activity and occupational exposures, limiting further evaluation of potential geneenvironment interactions that may modulate PCa risk. In addition, because of the limitations of directeral rectun examination, we may have some misclassification of disease among controls. Second, this study was a hospital-based study design, and thus may not represent the general population. However, all observed genotype frequencies in incident PCa patients and controls in our current study were in agreement with Hardy-Weinberg equilibrium, suggesting that any genotyping bias in our estimates of allele frequencies is unlikely to be substantial.
In conclusion, we provide the first evidence supporting the genetic effect of a CYR61 gene polymorphism on risk of PCa, particularly advanced PCa. We found that men carrying the G allele of rs3753793 have decreased PCa risk and decreased expression of CYR61 in related prostate tumors. Larger, population-based studies with more detailed environmental exposure data are needed to verify our findings derived from a hospital-based case-control study. 
